Danaher Co. (NYSE:DHR) Stock Holdings Lifted by Heartland Bank & Trust Co

Heartland Bank & Trust Co raised its position in shares of Danaher Co. (NYSE:DHR) by 52.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,322 shares of the conglomerate’s stock after purchasing an additional 1,148 shares during the period. Heartland Bank & Trust Co’s holdings in Danaher were worth $830,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Oak Thistle LLC acquired a new stake in Danaher in the second quarter valued at approximately $363,000. Caden Capital Partners LP lifted its stake in shares of Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after purchasing an additional 15,313 shares during the last quarter. HighPoint Advisor Group LLC bought a new stake in Danaher in the fourth quarter worth $2,614,000. Norden Group LLC acquired a new position in Danaher during the first quarter worth $4,151,000. Finally, Duality Advisers LP bought a new position in Danaher during the first quarter valued at about $5,573,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 0.9 %

DHR stock opened at $278.02 on Tuesday. The business’s 50-day simple moving average is $270.77 and its 200 day simple moving average is $258.06. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a market cap of $205.93 billion, a PE ratio of 47.12, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the business earned $2.05 earnings per share. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. On average, research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent analyst reports. Robert W. Baird upped their price target on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group upped their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Jefferies Financial Group began coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Finally, Evercore ISI lowered their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 over the last quarter. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.